Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SYK vs DXCM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DXCM Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–2 Matrix Metrics)
DXCM Overall Winner
6-Pillar Tally: SYK 3 – 3 DXCM
Matrix Metrics: SYK 2 – 7 DXCM
As of Nov 16, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Stryker Corporation (SYK) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas DXCM carries 53.8/100 (HOLD) at $81.58 (26.6x Forward P/E, 24.0% operating margin).
- Technical & Structure Timing Caution: SYK trades in a Neutral technical trend (SURGE options phase, RSI 51.5); meanwhile DXCM is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About SYK vs DXCM
SYK
Stryker Corporation
$310.79
+0.37% 1D
Market Cap
$118.9B
TTM Revenue
$26.3B
Forward P/E
19.0x
Beta / 30D Vol
0.22β · 50% Vol
Unified Composite Score
46.5
HOLD
Tech 37.0
Fund 49.0
Flow 58.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
DXCM
Head-to-Head Winner
DexCom, Inc.
$81.58
-2.11% 1D
Market Cap
$30.4B
TTM Revenue
$5.10B
Forward P/E
26.6x
Beta / 30D Vol
0.61β · 49% Vol
Unified Composite Score
53.8
HOLD
Tech 74.0
Fund 67.0
Flow 68.0
Mom 54.0
Weinstein Technical Phase
Distribution · Trim / tighten stop
6-Pillar Scorecard Institutional Category Breakdown (SYK 3 – 3 DXCM)
1. Valuation Multiples
SYK
Forward P/E
19.0x
26.6x
Trailing P/E
33.3x
32.0x
PEG Ratio
1.54x
1.27x
EV / Revenue
5.0x
6.0x
2. Growth & Scale
DXCM
Revenue Growth (YoY)
+7.6%
+11.2%
Earnings Growth (YoY)
-11.7%
+2.6%
TTM Revenue (USD)
$26.3B
$5.10B
Market Cap
$118.9B
$30.4B
3. Profitability & Quality
DXCM
Gross Margin
65.7%
63.4%
Operating Margin
24.0%
24.0%
Net Profit Margin
13.8%
19.4%
Return on Equity (ROE)
16.0%
37.7%
4. Balance Sheet & Cash Flow
DXCM
Cash Generation (TTM)
$4.57B
$1.73B
Cash Flow Margin
17.4%
33.9%
Net Cash / Leverage
$11.7B Net Debt (0.64x D/E)
$432M Net Debt (0.55x D/E)
Dividend Yield
1.10%
None (0.00%)
5. Options & Positioning
SYK
Options Structure Phase
SURGE
CONSOLIDATION
Current IV / %ile
28.1% (5th %ile)
36.9% (9th %ile)
Put/Call OI Skew
0.30x (Call-Skewed)
0.64x (Call-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Neutral
NEUTRAL · Distribution
6. R&D & Supply-Chain Moat
SYK
OpEx & R&D Intensity
41.7% of Rev ($11.0B)
39.4% of Rev ($2.01B)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Concentrated Oligopoly Moat
High-Margin Pricing Power Moat
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: SYK (2) vs DXCM (7)| Institutional Metric | SYK | DXCM | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $118.9B | $30.4B | SYK | |
| Trailing P/E Ratio | 33.3x | 32.0x | DXCM | |
| Forward P/E Ratio | 19.0x | 26.6x | SYK | |
| Revenue Growth (YoY) | +7.6% | +11.2% | DXCM | |
| Operating Margin (TTM) | 24.0% | 24.0% | Tie | |
| Net Profit Margin | 13.8% | 19.4% | DXCM | |
| Return on Equity (ROE) | 16.0% | 37.7% | DXCM | |
| 52-Week Range Position | 36% ($267–$389) | 69% ($57–$93) | DXCM | |
| Beta / 30D Volatility | 0.22β · 50% Vol | 0.61β · 49% Vol | DXCM | |
| Unified Institutional Score | 46.5 / 100 (HOLD) | 53.8 / 100 (HOLD) | DXCM | |
| Trailing 12M Revenue (USD) | $26.3B | $5.10B | Scale | |
| Gross Profit Margin (TTM) | 65.7% | 63.4% | Quality | |
| PEG Ratio & EV / Revenue | 1.54x PEG · 5.0x EV/Rev | 1.27x PEG · 6.0x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $4.57B ($11.7B Net Debt (0.64x D/E)) | $1.73B ($432M Net Debt (0.55x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
SYK +10.66 pp
3M Horizon
SYK +2.75 pp
6M Horizon
DXCM +26.11 pp
1Y Horizon
DXCM +53.37 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SYK Revenue | DXCM Revenue | SYK Op. Margin | DXCM Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $13.6B | $1.03B | 18.7% | -18.1% | SYK |
| FY2019 | $14.9B | $1.48B | 18.2% | 9.6% | SYK |
| FY2020 | $14.3B | $1.93B | 15.5% | 15.5% | Tie |
| FY2021 | $17.1B | $2.45B | 15.1% | 10.9% | SYK |
| FY2022 | $18.4B | $2.91B | 15.4% | 13.4% | SYK |
| FY2023 | $20.5B | $3.62B | 19.0% | 16.5% | SYK |
| FY2024 | $22.6B | $4.03B | 16.3% | 14.9% | SYK |
| FY2025 | $25.1B | $4.66B | 19.5% | 19.6% | DXCM |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
SYK
SURGE
Current IV
28.1%
IV Percentile
5th %ile
Put/Call OI Skew
0.30x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact SYK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
DXCM
CONSOLIDATION
Current IV
36.9%
IV Percentile
9th %ile
Put/Call OI Skew
0.64x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact DXCM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
SYK Moat Profile
Concentrated Oligopoly Moat
Medical Devices Operator
OpEx & R&D Reinvestment
41.7% of Rev ($11.0B)
90D Engineering Disclosures
0 Published · Surgical Robotics
DXCM Moat Profile
High-Margin Pricing Power Moat
Medical Devices Operator
OpEx & R&D Reinvestment
39.4% of Rev ($2.01B)
90D Engineering Disclosures
0 Published
Investor FAQ SYK vs DXCM Key Questions & Quantitative Answers
As of Nov 16, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Stryker Corporation (SYK) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas DXCM carries 53.8/100 (HOLD) at $81.58 (26.6x Forward P/E, 24.0% operating margin). Technical & Structure Timing Caution: SYK trades in a Neutral technical trend (SURGE options phase, RSI 51.5); meanwhile DXCM is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DXCM leads the Growth & Scale pillar: SYK posts +7.6% YoY revenue growth and -11.7% YoY earnings growth on $26.3B TTM revenue (65.7% gross margin, 24.0% operating margin), compared with DXCM at +11.2% YoY revenue growth and +2.6% YoY earnings growth on $5.10B TTM revenue (63.4% gross margin, 24.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SYK cumulative revenue shifted +84.7% while DXCM shifted +352.4%. In operating R&D and SG&A reinvestment, SYK deploys 41.7% of Rev ($11.0B) (0 90-day corporate R&D disclosures) versus 39.4% of Rev ($2.01B) (0 disclosures) for DXCM.
SYK screens cheaper on headline valuation multiples. SYK trades at 19.0x Forward P/E, 33.3x Trailing P/E, 1.54x PEG, and 5.0x EV/Revenue (17.4% FCF margin), whereas DXCM trades at 26.6x Forward P/E, 32.0x Trailing P/E, 1.27x PEG, and 6.0x EV/Revenue (33.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYK (16.0% ROE) versus DXCM (37.7% ROE) capital efficiency.
In options market volatility and institutional positioning, SYK carries 28.1% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.22β · 50% Vol realized risk). By comparison, DXCM carries 36.9% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.64x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.61β · 49% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
DXCM vs SYK · Reverse Pair
SYK vs MDT
· Sector Peer
SYK vs BDX
· Sector Peer
SYK vs TMO
· Sector Peer
DXCM vs PODD
· Sector Peer
DXCM vs IDXX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem